Illuminated spaces

Illumina Inc. has been handsomely rewarded by investors for its efforts to offer customers a complete set of systems for SNP genotyping and gene expression. Indeed, the stock has more than quadrupled in less than two years, as ILMN has consistently put out earnings that have eclipsed consensus estimates. Now, the company thinks it's added the third leg to its genetic research tools offerings via the planned acquisition of microarray and genetic services company Solexa Inc. for $600 million in stock.

ILMN's GoldenGate and Infinium assays cover genotyping and analog gene

Read the full 901 word article

How to gain access

Continue reading with a
two-week free trial.